Primary Site >> Colorectal Cancer
Gene >> ERCC1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. PMID: 9485007 |
Ref: Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. PMID: 10741696 |
Ref: Novel approaches in the treatment of non-small-cell lung cancer. PMID: 11301850 Ref: Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo. PMID: 11593056 Ref: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. PMID: 11731512 |
Ref: Pemetrexed combination therapy in the treatment of non-small cell lung cancer. PMID: 12023789 Ref: A sucrose-rich diet induces mutations in the rat colon. PMID: 12154038 Ref: Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer. PMID: 12437479 Ref: Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. PMID: 12480194 |
Ref: Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. PMID: 12504667 Ref: Implications of genetic testing in the management of colorectal cancer. PMID: 12749725 Ref: Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer. PMID: 12865926 Ref: Dietary elevated sucrose modulation of diesel-induced genotoxicity in the colon and liver of Big Blue rats. PMID: 12937889 Ref: ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. PMID: 16224397 |
Ref: Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. PMID: 15041737 Ref: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. PMID: 15213713 Ref: Tailored chemotherapy for colorectal cancer: a new approach to therapy. PMID: 15581057 |
Ref: Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. PMID: 15655543 Ref: Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. PMID: 15727486 Ref: Molecular markers that predict response to colon cancer therapy. PMID: 15934813 Ref: ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. PMID: 16144923 |
Ref: Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. PMID: 16609022 Ref: Effects of polymorphisms in ERCC1, ASE-1 and RAI on the risk of colorectal carcinomas and adenomas: a case control study. PMID: 16817948 Ref: Molecular determinants of irinotecan efficacy. PMID: 16894565 Ref: Increased mRNA expression levels of ERCC1, OGG1 and RAI in colorectal adenomas and carcinomas. PMID: 16914027 Ref: The optimal schedule for 5-fluorouracil radiosensitization in colon cancer cell lines. PMID: 17016597 Ref: Pharmacogenomics and colorectal cancer. PMID: 17163168 Ref: Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. PMID: 17241515 |
Ref: Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. PMID: 17242697 Ref: Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. PMID: 17401013 Ref: Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine. PMID: 18204222 |
Ref: Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. PMID: 17549067 Ref: Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation. PMID: 18182978 Ref: A haplotype of polymorphisms in ASE-1, RAI and ERCC1 and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a Danish prospective case-cohort study. PMID: 18289367 Ref: Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. PMID: 18442042 Ref: Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. PMID: 18448328 Ref: Mechanism of resistance to chemoradiation in p53 mutant human colon cancer. PMID: 18497992 Ref: Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. PMID: 18509181 Ref: Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma. PMID: 18565686 Ref: Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. PMID: 18797464 Ref: Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis. PMID: 19020759 Ref: Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine. PMID: 19105824 |
Ref: Red meat and poultry intake, polymorphisms in the nucleotide excision repair and mismatch repair pathways and colorectal cancer risk. PMID: 19029193 Ref: Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes. PMID: 19051292 Ref: ERCC1 codon 118 C-->T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. PMID: 19068092 Ref: Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. PMID: 19194123 Ref: Prognostic value of aspartyl (asparaginyl)-beta-hydroxylase/humbug expression in non-small cell lung carcinoma. PMID: 19200576 Ref: Functional evidence for Eme1 as a marker of cisplatin resistance. PMID: 19267403 Ref: Pharmacogenetics in chemotherapy of colorectal cancer. PMID: 19414151 Ref: Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. PMID: 19457654 Ref: Pharmacogenetics in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. PMID: 19581734 Ref: The overexpression of ERCC-1 is involved in the resistance of lung cancer cells to cetuximab combined with DDP. PMID: 20009541 Ref: Oxaliplatin: pre-clinical perspectives on the mechanisms of action, response and resistance. PMID: 22276017 |
Ref: Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. PMID: 19922504 Ref: Evidence of heterogeneity within colorectal liver metastases for allelic losses, mRNA level expression and in vitro response to chemotherapeutic agents. PMID: 20017140 Ref: Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines. PMID: 20020129 Ref: Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. PMID: 20078613 Ref: Expression profile of significant immortalization genes in colon cancer. PMID: 20127035 Ref: Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response. PMID: 20504250 Ref: Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells. PMID: 20682979 Ref: Deficient Pms2, ERCC1, Ku86, CcOI in field defects during progression to colon cancer. PMID: 20689513 Ref: Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. PMID: 20979931 Ref: Gene expression and effects of orally active derivatives of fluoropyrimidine on gastric and colorectal cancer. PMID: 22993546 |
Ref: Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. PMID: 20368715 Ref: ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. PMID: 21278243 Ref: Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. PMID: 21558395 Ref: Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients. PMID: 21787270 Ref: A review of excision repair cross-complementation group 1 in colorectal cancer. PMID: 21855036 Ref: Prognostic significance of thymidylate synthase expression in the adjuvant chemotherapy after resection for pulmonary metastases from colorectal cancer. PMID: 21868518 Ref: Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers? PMID: 21958378 Ref: Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer. PMID: 22110208 Ref: [Prediction of the efficacy of modified FOLFOX6 therapy according to the mRNA levels of thymidylate synthase (TS), excision repair cross-complementing-1 and -2( ERCC-1 and ERCC-2) and methylenetetrahydrofolate dehydrogenase( MTHFD) in the primary lesion o PMID: 22202336 Ref: [The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer]. PMID: 22202337 Ref: [Predictive marker for the efficacy of FOLFOX treatment in colon cancer (TS, ERCC1 etc)]. PMID: 22214010 |
Ref: X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients. PMID: 21167658 Ref: The C/A polymorphism in intron 11 of the XPC gene plays a crucial role in the modulation of an individual's susceptibility to sporadic colorectal cancer. PMID: 21559836 Ref: Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer. PMID: 21940361 Ref: Exploring biomarkers in head and neck cancer. PMID: 22281752 Ref: Deficient expression of DNA repair enzymes in early progression to sporadic colon cancer. PMID: 22494821 Ref: ERCC1 C118T associates with response to FOLFOX4 chemotherapy in colorectal cancer patients in Han Chinese. PMID: 22567180 Ref: [Study of the correlation between the colorectal cancer Chinese medicine syndrome types and (excision repair cross-complementing 1, ERCC1) gene polymorphisms]. PMID: 22679723 Ref: Thymidylate synthase and thymidine phosphorylase mRNA expression in primary lesions using laser capture microdissection is useful for prediction of the efficacy of FOLFOX treatment in colorectal cancer patients with liver metastasis. PMID: 22783377 Ref: Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients. PMID: 22909207 Ref: Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment? PMID: 22911546 Ref: GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population. PMID: 22994779 Ref: KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells. PMID: 23209813 Ref: Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction. PMID: 23272099 Ref: ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis. PMID: 24833529 |
Ref: KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients. PMID: 23175150 Ref: PPP1R13L variant associated with prognosis for patients with rectal cancer. PMID: 23180017 Ref: Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer. PMID: 23314736 Ref: Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer. PMID: 23332421 Ref: Induction of apoptosis and suppression of ERCC1 expression by the potent amonafide analogue 8-c in human colorectal carcinoma cells. PMID: 23426174 Ref: Polymorphisms in XPD and ERCC1 Associated with Colorectal Cancer Outcome. PMID: 23429196 Ref: ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy. PMID: 23481186 Ref: BRCA1 and ERCC1 mRNA levels are associated with lymph node metastasis in Chinese patients with colorectal cancer. PMID: 23496813 Ref: Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. PMID: 23543295 Ref: Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer. PMID: 23547850 Ref: Analysis of the mRNA expression of chemotherapy-related genes in colorectal carcinoma using the danenberg tumor profile method. PMID: 23577026 Ref: MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination. PMID: 23636450 Ref: MyD88 in DNA repair and cancer cell resistance to genotoxic drugs. PMID: 23766530 Ref: Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy. PMID: 23996617 Ref: Use of molecular biomarkers to inform adjuvant therapy for colon cancer. PMID: 24133820 Ref: Polymorphisms of GSTP1, ERCC2 and TS-3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients. PMID: 24137384 Ref: An explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohort. PMID: 24144331 Ref: Multigene assays in metastatic colorectal cancer. PMID: 24158971 Ref: [Clinical values of detecting excision repair cross complementing 1 and top-isomerase I in individualized therapies of metastatic colorectal cancer]. PMID: 24548447 |
Ref: Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin. PMID: 24220697 Ref: Cinnamaldehyde/chemotherapeutic agents interaction and drug-metabolizing genes in colorectal cancer. PMID: 24276478 Ref: Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil. PMID: 24520224 Ref: Association of ERCC1 and ERCC2 polymorphisms with colorectal cancer risk in a Chinese population. PMID: 24531312 Ref: Measuring ERCC1 protein expression in cancer specimens: validation of a novel antibody. PMID: 24603753 Ref: ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy. PMID: 24847383 Ref: Association of single nucleotide polymorphisms of ERCC1 and XPF with colorectal cancer risk and interaction with tobacco use. PMID: 24861646 Ref: CYP1A1 Ile462Val polymorphism and colorectal cancer risk in Polish patients. PMID: 24939416 Ref: Novel diet-related mouse model of colon cancer parallels human colon cancer. PMID: 25024814 Ref: [Validation of genetic polymorphisms associated to the toxicity of chemotherapy in colorectal cancer patients]. PMID: 25137161 Ref: Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy. PMID: 25175730 Ref: Colorectal cancer in Chinese patients: current and emerging treatment options. PMID: 25336973 Ref: The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies. PMID: 25339033 Ref: Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. PMID: 25370899 |
Ref: EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer. PMID: 25026457 Ref: Gene expression differences in primary colorectal tumors and matched liver metastases: chemotherapy related or tumoral heterogeneity? PMID: 25301403 Ref: Tissue-specific selection of optimal reference genes for expression analysis of anti-cancer drug-related genes in tumor samples using quantitative real-time RT-PCR. PMID: 25445497 Ref: Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. PMID: 25532759 Ref: ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas. PMID: 25553091 Ref: Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation. PMID: 25589620 Ref: Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. PMID: 25677447 Ref: DNA repair gene polymorphisms do not predict response to radiotherapy-based multimodality treatment of patients with rectal cancer: a meta-analysis. PMID: 25684513 Ref: XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population. PMID: 25690281 Ref: Association between ERCC1 and XPF polymorphisms and risk of colorectal cancer. PMID: 25730007 Ref: Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis. PMID: 25834456 Ref: ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy. PMID: 26161372 Ref: ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting. PMID: 26161376 Ref: Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study. PMID: 26372896 |
Ref: Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer. PMID: 24517959 Ref: Enhancement of oxaliplatin sensitivity in human colorectal cancer by hypericin mediated photodynamic therapy via ROS-related mechanism. PMID: 26673998 Ref: Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis. PMID: 26676887 Ref: Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy. PMID: 26904994 Ref: Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis. PMID: 27636246 |
Ref: ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt. PMID: 28088319 Ref: Medical Oncologists' Experiences in Using Genomic Testing for Lung and Colorectal Cancer Care. PMID: 28095174 Ref: Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis. PMID: 28280620 Ref: Effect of antitumor drugs in low concentrationson the biological, immunophenotypic and cytogenetic characteristics of human colon cancer cells in vitro. PMID: 28361849 Ref: The Contribution of Excision Repair Cross-complementing Group 1 Genotypes to Colorectal Cancer Susceptibility in Taiwan. PMID: 28476796 Ref: Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy. PMID: 28608017 Ref: Systematic immunohistochemical screening for mismatch repair and ERCC1 gene expression from colorectal cancers in China: Clinicopathological characteristics and effects on survival. PMID: 28767665 Ref: Expression of ERCC1, RRM1, TUBB3 in correlation with apoptosis repressor ARC, DNA mismatch repair proteins and p53 in liver metastasis of colorectal cancer. PMID: 28949378 Ref: Evidence for an Association of ERCC1 Expression and Mismatch Repair Status with Overall Survival in Colorectal Cancer Patients. PMID: 29065415 Ref: Polymorphisms of cancer-related genes and risk of multipleprimary malignancies involving colorectal cancer PMID: 29151331 Ref: Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients. PMID: 29153096 Ref: Association of ERCC1 Polymorphisms with the Risk of Colorectal Cancer: A Meta-Analysis. PMID: 29199611 |
Ref: Promoter methylation and expression of DNA repair genes MGMT and ERCC1 in tissue and blood of rectal cancer patients. PMID: 29080834 Ref: Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. PMID: 29145602 Ref: Differential Regulation of LET-7 by LIN28B Isoform-Specific Functions. PMID: 29330293 Ref: Loss of CDX2 gene expression is associated with DNA repair proteins and is a crucial member of the Wnt signaling pathway in liver metastasis of colorectal cancer. PMID: 29467879 Ref: The polymorphisms of miRNA-binding site in MLH3 and ERCC1 were linked to the risk of colorectal cancer in a case-control study. PMID: 29516665 Ref: The Differential Expression of Core Genes in Nucleotide Excision Repair Pathway Indicates Colorectal Carcinogenesis and Prognosis. PMID: 29568775 Ref: Using patient-derived xenograft models of colorectal liver metastases to predict chemosensitivity. PMID: 29804848 Ref: Thymidylate synthase expression in primary colorectal cancer as a predictive marker for the response to 5-fluorouracil- and oxaliplatin-based preoperative chemotherapy for liver metastases. PMID: 29977534 Ref: Unexpected Growth-Promoting Effect of Oxaliplatin in Excision Repair Cross-Complementation Group 1 Transfected Human Colon Cancer Cells. PMID: 30048976 Ref: Nucleotide Excision Repair Factor XPC Ameliorates Prognosis by Increasing the Susceptibility of Human Colorectal Cancer to Chemotherapy and Ionizing Radiation. PMID: 30109214 |